Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, part of a doubling of its investment in manufacturing.

Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

Eli Lilly plans to spend $27 billion to build new drug manufacturing sites in the U.S., at a time when President Trump is seeking to press drugmakers to move stateside.

The pharmaceutical firm is growing its presence across three states, creating 3,000 jobs.

The story has been updated to correct the new site locations At a press conference in Washington, D.C., Eli Lilly And Co (NYSE:LLY) announced its plans to bolster its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States.

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.